As an added bonus, sign up and you'll have free and immediate access to our Member's Only Special Report, "The Two Most Important Rules to Investing", revealing valuable information for successful investing.
May 24, 2013 10:17 AM PDT
One of the biopharmaceutical companies that has been lagging the stellar performance of its peers is Exelixis (NADSAQ: EXEL), developer of the compound cabozantinib. Cabo, which was FDA approved last year for the treatment of medullary thyroid cancer (MTC), is now being marketed under the trade name COMETRIQ. In the company’s reported Q1 2013 earnings release on May 7th, the company was able to present some early results for the drug’s performance on the open market although it’s difficult to accurately interpret a drug’s intrinsic monetary potential with only a few weeks of sales data and estimates on the drug’s penetration into a market.
